Human FcRn / FCGRT&B2M Heterodimer Protein, Strep Tag&Tag Free (MALS & SPR verified)
分子別名（Synonym）
FcRn,FCGRT & B2M
表達(dá)區(qū)間及表達(dá)系統(tǒng)（Source）
Human FCGRT&B2M Heterodimer Protein, Strep Tag&Tag Free (FCM-H5283) is expressed from human 293 cells (HEK293). It contains AA Ala 24 - Ser 297 (FCGRT) & Ile 21 - Met 119 (B2M) (Accession # P55899-1 (FCGRT) & P61769-1 (B2M)).
Predicted N-terminus: Ala 24 (FCGRT) & Ile 21 (B2M)
蛋白結(jié)構(gòu)（Molecular Characterization）
Human FCGRT&B2M Heterodimer Protein, Strep Tag&Tag Free, produced by co-expression of FCGRT and B2M, has a calculated MW of 33.8 kDa (FCGRT) and 11.7 kDa (B2M). Subunit FCGRT is fused with Strep II-tag at the C-terminus and subunit Beta-2 microglobulin (B2M) contains no tag. The reducing (R) protein migrates as 40-43 kDa (FCGRT) and 12 kDa (B2M) respectively due to glycosylation.
內(nèi)毒素（Endotoxin）
Less than 1.0 EU per μg by the LAL method / rFC method.
純度（Purity）
>90% as determined by SDS-PAGE.
>95% as determined by SEC-MALS.
制劑（Formulation）
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
重構(gòu)方法（Reconstitution）
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
存儲（Storage）
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.
背景介紹
FCGRT & B2M異源二聚體蛋白（FcRn復(fù)合物） 由兩個亞基組成：p51（即FCGRT）和p14（即β2-微球蛋白），形成MHC I類樣異源二聚體結(jié)構(gòu)。
IgG Fc片段受體轉(zhuǎn)運蛋白α（FCGRT） 可結(jié)合單體免疫球蛋白γ的Fc區(qū)，并介導(dǎo)乳汁中IgG的攝取；該蛋白可能在母胎間免疫球蛋白G轉(zhuǎn)運中發(fā)揮作用。
β2-微球蛋白（B2M） 是I類主要組織相容性復(fù)合體（MHC）的組成成分，參與向免疫系統(tǒng)呈遞肽類抗原。
關(guān)鍵字： FcRn (FCGRT & B2M);FcRn蛋白;B2M重組蛋白;ACRO;百普賽斯;
百普賽斯集團(tuán)ACROBiosystems Group（股票代碼：301080）是成立于2010年的跨國生物科技公司，是為全球生物醫(yī)藥、健康產(chǎn)業(yè)領(lǐng)域提供關(guān)鍵生物試劑產(chǎn)品及解決方案的行業(yè)平臺型基石企業(yè)。2021年在創(chuàng)業(yè)板上市。百普賽斯集團(tuán)業(yè)務(wù)遍布全球，橫跨亞洲、北美洲、歐洲，在中國、美國、瑞士等12個城市設(shè)有辦公室、研發(fā)中心及生產(chǎn)基地。目前累計服務(wù)客戶超6000家，與全球Top 20醫(yī)藥企業(yè)均建立了長期、穩(wěn)定的合作伙伴關(guān)系。集團(tuán)旗下?lián)碛衅放艫CROBiosystems百普賽斯、bioSeedin柏思薈、Condense Capital墾拓資本和ACRODiagnostics百斯醫(yī)學(xué)等。